Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer

Required: KRAS mutation

RAS mutation and MMR status must be determined (or tissue availability for testing if not already determined)

Required: NRAS mutation

RAS mutation and MMR status must be determined (or tissue availability for testing if not already determined)

Required: MMR status determined

RAS mutation and MMR status must be determined (or tissue availability for testing if not already determined)

Allowed: KRAS wild-type

antibody therapy with bevacizumab and an anti-EGFR antibody, if RAS wild type, should have been given unless medical reasons have precluded their use

Allowed: NRAS wild-type

antibody therapy with bevacizumab and an anti-EGFR antibody, if RAS wild type, should have been given unless medical reasons have precluded their use

Must have received: antimetabolite (5-FU)

progressed after standard therapy that included 5-FU

Must have received: topoisomerase inhibitor (irinotecan)

progressed after standard therapy that included irinotecan

Must have received: platinum-based chemotherapy (oxaliplatin)

progressed after standard therapy that included oxaliplatin

Must have received: antibody-drug conjugate (bevacizumab)

antibody therapy with bevacizumab ... should have been given unless medical reasons have precluded their use

Must have received: anti-EGFR antibody

antibody therapy with ... an anti-EGFR antibody, if RAS wild type, should have been given unless medical reasons have precluded their use

Cannot have received: (TAS-102)

Participants who have previously received TAS-102